Claims

1. A COMPOUND characterized by having the general formula (II):



(II)

wherein

X is an oxygen atom;

A represents a linear alkyl C_{2-4}group which may have one or more of its hydrogens replaced by an alkyl group selected from methyl, ethyl, propyl or isopropyl;

R_1 represents an alkyl C_{1-6} or alkenyl C_{2-6} or alkynyl C_{2-6} or haloalkyl C_{1-6} or cycloalkyl C_{3-6} or C_{1-2}-alkyl cycloalkyl-C_{3-6} group;

R_2 represents a hydrogen or an alkyl C_{1-3}group;

n is 0 or 1;

p is 1 or 2.

2. THE COMPOUND, according to claim 1,characterized in that the compound of the general formula (II) is selected from the group consisting of:

- -N-(2-(2-ethoxy-7,8-dihydro-1H-benzofuran[4,5-d]imidazole-1-yl)ethyl)acetamide;
- -N-(2-(2-methoxy-7,8-dihydro-1H-benzofuran[4,5-d]imidazole-1-yl)ethyl)acetamide.

3. PROCESS FOR OBTAINING THE COMPOUND of general formula (IIa)



characterized for comprising the following steps:

(a) reacting a compound of formula (IX)



(IX)

with an tetraalkylorthocarbonate selected from the group comprising tetramethylorthocarbonate and tetraethyl orthocarbonate, to obtain a compound of formula (X)



(X)

wherein R_2, n is 0 or 1; p is 1 or 2;

(b) reacting the compound of formula (X) obtained in step (a) with a deprotecting agent to obtain a compound of formula (XI)



(XI)

(c) reacting the compound of formula (XI) obtained in (b) with a carboxylic acid anhydride of formula (IV)



(IV),

or with a carboxylic acid halide of formula (V)



(V)

wherein R_1 is as described for the compound of formula(II) in claim 1, and X_1 represents a bromine or chlorine atom.

4. A PHARMACEUTICAL COMPOSITION characterized by comprising:

a) at least one compound of formula (II):



(II)

wherein

X corresponds to an oxygen atom;

A corresponds to a linear alkyl C_{2-4} group, which may have one or more of its hydrogens substituted by an alkyl group selected from methyl, ethyl, propyl or isopropyl;

R_1 is an alkyl C_{1-6}, or alkenyl C_{2-6}, or alkynyl C_{2-6}, or haloalkyl C_{1-6}, or cycloalkyl C_{3-6}, or C_{1-2}-alkyl-cycloalkyl C_{3-6} group;

R_2 is a hydrogen or a alkyl C_{1-3} group;

n is 0 or 1;

p is 1 or 2, and

b) pharmaceutically acceptable vehicle.

5. PHARMACEUTICAL COMPOSITION, according to claim 11, characterized in that the compound of formula (II) is selected from the group consisting of:

- *N*-(2-(2-ethoxy-7,8-dihydro-1*H*-benzofuran[4,5-d] imidazole-1-yl)ethyl)acetamide;
- *N*-(2-(2-methoxy-7,8-dihydro-1*H*-benzofuran[4,5-d] imidazole-1-yl)ethyl)acetamide.

6. USE OF THE COMPOUND of formula (II), according to claim 2, characterized in that it is for the manufacture of a drug for the treatment of psychiatric disorders and/or sleep disorders.